Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co. (2579667), recently launched ABILIFY® DISCMELT™ (a pdf file) (aripiprazole) Orally Disintegrating Tablets, a new oral form of the antipsychotic medication ABILIFY® (aripiprazole) that rapidly disintegrates in the mouth.
It has been shown in pharmacokinetic studies that ABILIFY® DISCMELT™ Orally Disintegrating Tablets are bioequivalent of the regular ABILIFY tablets, thereby offering similar efficacy and safety at the same doses as the oral tablets.
In this new oral form, ABILIFY® DISCMELT™ provides a convenient alternative for adults with schizophrenia or manic episodes associated with Bipolar I Disorder.
Read the full press release."Many adults with schizophrenia or Bipolar I Disorder, both in inpatient and outpatient settings, don't take their medication as prescribed," said John Zajecka, M.D., Director, Psychiatry Treatment Research Center and Associate Professor, Department of Psychiatry, Rush University Medical Center in Chicago.
"ABILIFY DISCMELT provides healthcare professionals a formulation alternative that may be desirable for some adult patients."
» Abilify May Be Effective in Treating Alcohol Addiction from PharmaGazette
Dr. Henry R. Kranzler and colleagues from the University of Connecticut Health Center, Farmington believe that the use of Abilify (aripiprazole) may be of use to patients battling an addiction to alcohol.Abilify, a drug used to treat the symptoms of... [Read More]
Tracked on: April 23, 2008 8:27 AM | Permalink to Trackback